Murcia O, Juárez M, Hernández-Illán E, Egoavil C, Giner-Calabuig M, Rodríguez-Soler M, Jover R. Serrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapy. World J Gastroenterol 2016; 22(13): 3516-3530 [PMID: 27053844 DOI: 10.3748/wjg.v22.i13.3516]
Corresponding Author of This Article
Dr. Rodrigo Jover, Unidad de Gastroenterología, Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria Isabial, 12 Pintor Baeza, 03010 Alicante, Spain. rodrigojover@gmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Apr 7, 2016; 22(13): 3516-3530 Published online Apr 7, 2016. doi: 10.3748/wjg.v22.i13.3516
Serrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapy
Oscar Murcia, Miriam Juárez, Eva Hernández-Illán, Cecilia Egoavil, Mar Giner-Calabuig, María Rodríguez-Soler, Rodrigo Jover
Oscar Murcia, Miriam Juárez, Eva Hernández-Illán, Cecilia Egoavil, Mar Giner-Calabuig, María Rodríguez-Soler, Rodrigo Jover, Unidad de Gastroenterología, Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria Isabial, 03010 Alicante, Spain
Author contributions: Murcia O wrote the first draft of the manuscript; Juárez M, Hernández-Illán E, Egoavil C and Giner-Calabuig M critically reviewed and corrected the manuscript; Rodríguez-Soler M and Jover R set the last version of this manuscript.
Conflict-of-interest statement: No potential conflicts of interest relevant to this article were reported.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Rodrigo Jover, Unidad de Gastroenterología, Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria Isabial, 12 Pintor Baeza, 03010 Alicante, Spain. rodrigojover@gmail.com
Telephone: +34-965-933468 Fax: +34-965-933468
Received: November 11, 2015 Peer-review started: November 12, 2015 First decision: November 27, 2015 Revised: December 4, 2015 Accepted: January 30, 2016 Article in press: January 30, 2016 Published online: April 7, 2016
Abstract
Molecular advances support the existence of an alternative pathway of colorectal carcinogenesis that is based on the hypermethylation of specific DNA regions that silences tumor suppressor genes. This alternative pathway has been called the serrated pathway due to the serrated appearance of tumors in histological analysis. New classifications for colorectal cancer (CRC) were proposed recently based on genetic profiles that show four types of molecular alterations: BRAF gene mutations, KRAS gene mutations, microsatellite instability, and hypermethylation of CpG islands. This review summarizes what is known about the serrated pathway of CRC, including CRC molecular and clinical features, prognosis, and response to chemotherapy.
Core tip: Recently, the implication among colorectal cancers with methylator phenotype has burst into the gastroenterology literature. In this review, we analyze the correlation between serrated cancers, the methylator phenotype and other genetic features in order to assess their prognosis and response to adjuvant chemotherapy.
